<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Clin Trials</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Clin Trials</journal-id><journal-id journal-id-type="publisher-id">pctr</journal-id><journal-id journal-id-type="publisher-id">plct</journal-id><journal-id journal-id-type="pmc">plosclin</journal-id><journal-title-group><journal-title>PLoS Clinical Trials</journal-title></journal-title-group><issn pub-type="epub">1555-5887</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17476314</article-id><article-id pub-id-type="pmc">1863514</article-id><article-id pub-id-type="doi">10.1371/journal.pctr.0020016</article-id><article-id pub-id-type="publisher-id">06-PLCT-CT-00054R2</article-id><article-id pub-id-type="sici">plct-02-04-04</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Nutrition</subject><subject>Pharmacology</subject><subject>Public Health and Epidemiology</subject></subj-group></article-categories><title-group><article-title>A Randomized, Double-Blind, Placebo-Controlled Trial of <named-content content-type="genus-species">Lessertia frutescens</named-content> in Healthy Adults</article-title><alt-title alt-title-type="running-head">Clinical Trial of<italic>Lessertia frutescens</italic></alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>Quinton</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Syce</surname><given-names>James</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nell</surname><given-names>Haylene</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rudeen</surname><given-names>Kevin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Folk</surname><given-names>William R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref></contrib></contrib-group><aff id="aff1"><label>1</label> South African Herbal Science and Medicine Institute, University of the Western Cape, Bellville, South Africa
</aff><aff id="aff2"><label>2</label> The International Centre for Indigenous Phytotherapy Studies, University of the Western Cape, Bellville, South Africa
</aff><aff id="aff3"><label>3</label> Tiervlei Trial Centre, Karl Bremer Hospital, Bellville, South Africa
</aff><aff id="aff4"><label>4</label> School of Health Professions, University of Missouri-Columbia, Missouri, United States of America
</aff><aff id="aff5"><label>5</label> School of Medicine, University of Missouri-Columbia, Missouri, United States of America
</aff><author-notes><corresp id="cor1">* To whom correspondence should be addressed. E-mail: <email>qjohnson@uwc.ac.za</email></corresp></author-notes><pub-date pub-type="collection"><month>4</month><year>2007</year></pub-date><pub-date pub-type="epub"><day>27</day><month>4</month><year>2007</year></pub-date><volume>2</volume><issue>4</issue><elocation-id>e16</elocation-id><history><date date-type="received"><day>18</day><month>9</month><year>2006</year></date><date date-type="accepted"><day>20</day><month>2</month><year>2007</year></date></history><permissions><copyright-statement> © 2007 Johnson et al.</copyright-statement><copyright-year>2007</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="4419" xml_f="4430" txt_i="11" txt_f="22">Objectives:</offsets></title><p><offsets xml_i="4441" xml_f="4688" txt_i="23" txt_f="270">Indigenous medicines are widely used throughout Africa, despite a lack of scientific evidence for their safety or efficacy. The aims of this study were: (a) to conduct a pilot study of the safety of a common indigenous South African phytotherapy, </offsets><italic><offsets xml_i="4696" xml_f="4731" txt_i="270" txt_f="305">Lessertia frutescens (Sutherlandia)</offsets></italic><offsets xml_i="4740" xml_f="4898" txt_i="305" txt_f="463">, in healthy adults; and (b) to contribute to establishing procedures for ethical and scientifically rigorous clinical trials of African indigenous medicines.</offsets></p></sec><sec id="st2"><title><offsets xml_i="4929" xml_f="4936" txt_i="465" txt_f="472">Design:</offsets></title><p><offsets xml_i="4947" xml_f="5003" txt_i="473" txt_f="529">A randomized, double-blind, placebo-controlled trial of </offsets><italic><offsets xml_i="5011" xml_f="5023" txt_i="529" txt_f="541">Sutherlandia</offsets></italic><offsets xml_i="5032" xml_f="5063" txt_i="541" txt_f="572"> leaf powder in healthy adults.</offsets></p></sec><sec id="st3"><title><offsets xml_i="5094" xml_f="5102" txt_i="574" txt_f="582">Setting:</offsets></title><p><offsets xml_i="5113" xml_f="5182" txt_i="583" txt_f="652">Tiervlei Trial Centre, Karl Bremer Hospital, Bellville, South Africa.</offsets></p></sec><sec id="st4"><title><offsets xml_i="5213" xml_f="5226" txt_i="654" txt_f="667">Participants:</offsets></title><p><offsets xml_i="5237" xml_f="5405" txt_i="668" txt_f="836">25 adults who provided informed consent and had no known significant diseases or allergic conditions nor clinically abnormal laboratory blood profiles during screening.</offsets></p></sec><sec id="st5"><title><offsets xml_i="5436" xml_f="5449" txt_i="838" txt_f="851">Intervention:</offsets></title><p><offsets xml_i="5460" xml_f="5534" txt_i="852" txt_f="926">12 participants randomized to a treatment arm consumed 400 mg capsules of </offsets><italic><offsets xml_i="5542" xml_f="5554" txt_i="926" txt_f="938">Sutherlandia</offsets></italic><offsets xml_i="5563" xml_f="5743" txt_i="938" txt_f="1118"> leaf powder twice daily (800 mg/d). 13 individuals randomized to the control arm consumed a placebo capsule. Each participant received 180 capsules for the trial duration of 3 mo.</offsets></p></sec><sec id="st6"><title><offsets xml_i="5774" xml_f="5791" txt_i="1120" txt_f="1137">Outcome Measures:</offsets></title><p><offsets xml_i="5802" xml_f="5938" txt_i="1138" txt_f="1274">The primary endpoint was frequency of adverse events; secondary endpoints were changes in physical, vital, blood, and biomarker indices.</offsets></p></sec><sec id="st7"><title><offsets xml_i="5969" xml_f="5977" txt_i="1276" txt_f="1284">Results:</offsets></title><p><offsets xml_i="5988" xml_f="6143" txt_i="1285" txt_f="1440">There were no significant differences in general adverse events or physical, vital, blood, and biomarker indices between the treatment and placebo groups (</offsets><italic><offsets xml_i="6151" xml_f="6152" txt_i="1440" txt_f="1441">p</offsets></italic><offsets xml_i="6161" xml_f="6206" txt_i="1441" txt_f="1483"> &gt; 0.05). However, participants consuming </offsets><italic><offsets xml_i="6214" xml_f="6226" txt_i="1483" txt_f="1495">Sutherlandia</offsets></italic><offsets xml_i="6235" xml_f="6303" txt_i="1495" txt_f="1563"> reported improved appetite compared to those in the placebo group (</offsets><italic><offsets xml_i="6311" xml_f="6312" txt_i="1563" txt_f="1564">p</offsets></italic><offsets xml_i="6321" xml_f="6396" txt_i="1564" txt_f="1639"> = 0.01). Although the treatment group exhibited a lower respiration rate (</offsets><italic><offsets xml_i="6404" xml_f="6405" txt_i="1639" txt_f="1640">p</offsets></italic><offsets xml_i="6414" xml_f="6453" txt_i="1640" txt_f="1676"> &lt; 0.04) and higher platelet count (</offsets><italic><offsets xml_i="6461" xml_f="6462" txt_i="1676" txt_f="1677">p</offsets></italic><offsets xml_i="6471" xml_f="6486" txt_i="1677" txt_f="1692"> = 0.03), MCH (</offsets><italic><offsets xml_i="6494" xml_f="6495" txt_i="1692" txt_f="1693">p</offsets></italic><offsets xml_i="6504" xml_f="6520" txt_i="1693" txt_f="1709"> = 0.01), MCHC (</offsets><italic><offsets xml_i="6528" xml_f="6529" txt_i="1709" txt_f="1710">p</offsets></italic><offsets xml_i="6538" xml_f="6563" txt_i="1710" txt_f="1735"> = 0.02), total protein (</offsets><italic><offsets xml_i="6571" xml_f="6572" txt_i="1735" txt_f="1736">p</offsets></italic><offsets xml_i="6581" xml_f="6604" txt_i="1736" txt_f="1759"> = 0.03), and albumin (</offsets><italic><offsets xml_i="6612" xml_f="6613" txt_i="1759" txt_f="1760">p</offsets></italic><offsets xml_i="6622" xml_f="6760" txt_i="1760" txt_f="1898"> = 0.03), than the placebo group, these differences remained within the normal physiological range, and were not clinically relevant. The </offsets><italic><offsets xml_i="6768" xml_f="6780" txt_i="1898" txt_f="1910">Sutherlandia</offsets></italic><offsets xml_i="6789" xml_f="6850" txt_i="1910" txt_f="1971"> biomarker canavanine was undetectable in participant plasma.</offsets></p></sec><sec id="st8"><title><offsets xml_i="6881" xml_f="6892" txt_i="1973" txt_f="1984">Conclusion:</offsets></title><p><offsets xml_i="6903" xml_f="6927" txt_i="1985" txt_f="2009">Consumption of 800 mg/d </offsets><italic><offsets xml_i="6935" xml_f="6947" txt_i="2009" txt_f="2021">Sutherlandia</offsets></italic><offsets xml_i="6956" xml_f="7019" txt_i="2021" txt_f="2084"> leaf powder capsules for 3 mo was tolerated by healthy adults.</offsets></p></sec></abstract><abstract abstract-type="editor"><title><offsets xml_i="7080" xml_f="7100" txt_i="2097" txt_f="2117">Editorial Commentary</offsets></title><sec id="st9"><title></title><p><offsets xml_i="7140" xml_f="7141" txt_i="2119" txt_f="2120">
</offsets><bold><offsets xml_i="7147" xml_f="7158" txt_i="2120" txt_f="2131">Background:</offsets></bold><offsets xml_i="7165" xml_f="7272" txt_i="2131" txt_f="2238"> In Africa, traditional herbal medicines are given for many illnesses. In particular, one herbal medicine, </offsets><italic><offsets xml_i="7280" xml_f="7315" txt_i="2238" txt_f="2273">Sutherlandia (Lessertia frutescens)</offsets></italic><offsets xml_i="7324" xml_f="8141" txt_i="2273" txt_f="3090"> is commonly given in the belief that this herb will treat some of the symptoms associated with HIV/AIDS, such as nausea and lack of appetite, amongst others. However, there is very little evidence relating to the safety and none to the efficacy of this herb. Generally, when new drugs are developed, the first stage of human testing involves a Phase 1 trial. This type of trial would typically involve small numbers of healthy individuals, who would receive progressively increasing doses of the drug under study, and would be closely monitored for any sign of side effects. Phase 1 trials would typically also collect data from blood samples to find out how the drug is handled in the body and broken down and eliminated. Therefore, the researchers here carried out a preliminary study to assess just the safety of </offsets><italic><offsets xml_i="8149" xml_f="8161" txt_i="3090" txt_f="3102">Sutherlandia</offsets></italic><offsets xml_i="8170" xml_f="8259" txt_i="3102" txt_f="3191">. 25 healthy adults were randomized to receive either tablets containing a fixed dose of </offsets><italic><offsets xml_i="8267" xml_f="8279" txt_i="3191" txt_f="3203">Sutherlandia</offsets></italic><offsets xml_i="8288" xml_f="8727" txt_i="3203" txt_f="3642"> leaf powder daily for three months, or matched placebo tablets containing lettuce leaf powder, for the same period of time. The main aim of the trial was to assess safety, so the primary outcomes were adverse events experienced by the participants. The researchers also measured standard outcomes such as blood pressure, heart rate, body weight, urine glucose, protein, and many others, at one-month intervals over the three-month period.</offsets></p><p><offsets xml_i="8734" xml_f="8735" txt_i="3643" txt_f="3644">
</offsets><bold><offsets xml_i="8741" xml_f="8762" txt_i="3644" txt_f="3665">What the trial shows:</offsets></bold><offsets xml_i="8769" xml_f="9545" txt_i="3665" txt_f="4441"> Adverse events experienced by trial participants over the three months of this trial included those that might be expected in a group of otherwise healthy individuals, such as headaches, insomnia, allergies, malaise, palpitations, nosebleeds, and so on. The researchers did not see statistically significant differences between treatment and placebo groups in any of the major categories of these events. Most physical and laboratory measurements also showed no statistically significant differences between the study groups. However, there were statistically significant, but small, differences between groups in respiratory rate and in various basic blood tests. The researchers did not think these differences were clinically important. Overall, this trial suggested that </offsets><italic><offsets xml_i="9553" xml_f="9565" txt_i="4441" txt_f="4453">Sutherlandia</offsets></italic><offsets xml_i="9574" xml_f="9656" txt_i="4453" txt_f="4535"> use was not associated with side effects at this dosage and over this time scale.</offsets></p><p><offsets xml_i="9663" xml_f="9664" txt_i="4536" txt_f="4537">
</offsets><bold><offsets xml_i="9670" xml_f="9696" txt_i="4537" txt_f="4563">Strengths and limitations:</offsets></bold><offsets xml_i="9703" xml_f="9801" txt_i="4563" txt_f="4661"> Strengths of this study include the use of randomization to distribute individuals to either the </offsets><italic><offsets xml_i="9809" xml_f="9821" txt_i="4661" txt_f="4673">Sutherlandia</offsets></italic><offsets xml_i="9830" xml_f="9985" txt_i="4673" txt_f="4828"> or control groups, and in the use of a placebo control group, which therefore allowed the researchers to compare the frequencies of adverse events in the </offsets><italic><offsets xml_i="9993" xml_f="10005" txt_i="4828" txt_f="4840">Sutherlandia</offsets></italic><offsets xml_i="10014" xml_f="10446" txt_i="4840" txt_f="5272"> group with what might be expected among healthy individuals over the course of three months. An important limitation is the small sample size of the trial. This size limits the sensitivity of the trial to detect rare adverse events to the herb under study, and therefore one cannot say conclusively that the herb is safe, based on this data. Additionally, the study looked only at the participants' response to one dosage level of </offsets><italic><offsets xml_i="10454" xml_f="10466" txt_i="5272" txt_f="5284">Sutherlandia</offsets></italic><offsets xml_i="10475" xml_f="10954" txt_i="5284" txt_f="5763">. A strategy using progressively increasing doses would have allowed the researchers to see if there was a maximum tolerated dose to this herb. A further limitation in this study is the lack of data relating to how the herb is broken down in the body; these data are normally an important part of Phase 1 trials and, combined with safety data, are crucial to finding out whether a compound is safe when given at a dosage that allows it to be available to the appropriate tissues.</offsets></p><p><offsets xml_i="10961" xml_f="10962" txt_i="5764" txt_f="5765">
</offsets><bold><offsets xml_i="10968" xml_f="10997" txt_i="5765" txt_f="5794">Contribution to the evidence:</offsets></bold><offsets xml_i="11004" xml_f="11069" txt_i="5794" txt_f="5859"> Data from previous studies in nonhuman primates have shown that </offsets><italic><offsets xml_i="11077" xml_f="11089" txt_i="5859" txt_f="5871">Sutherlandia</offsets></italic><offsets xml_i="11098" xml_f="11284" txt_i="5871" txt_f="6057"> is not associated with toxic or other side effects at approximately equivalent or higher doses than that normally taken by people with HIV/AIDS. This study adds safety data relating to </offsets><italic><offsets xml_i="11292" xml_f="11304" txt_i="6057" txt_f="6069">Sutherlandia</offsets></italic><offsets xml_i="11313" xml_f="11472" txt_i="6069" txt_f="6228"> consumption in healthy humans, which confirm the primate data. However, it is crucial to collect more data relating to how the probable active ingredients of </offsets><italic><offsets xml_i="11480" xml_f="11492" txt_i="6228" txt_f="6240">Sutherlandia</offsets></italic><offsets xml_i="11501" xml_f="11654" txt_i="6240" txt_f="6393"> are absorbed and broken down, and to assess safety at different dosages, before studies are even considered for the next stage, which is to see whether </offsets><italic><offsets xml_i="11662" xml_f="11674" txt_i="6393" txt_f="6405">Sutherlandia</offsets></italic><offsets xml_i="11683" xml_f="11725" txt_i="6405" txt_f="6447"> has any efficacy in people with HIV/AIDS.</offsets></p></sec></abstract><counts><page-count count="7"></page-count></counts><custom-meta-group><custom-meta><meta-name>citation</meta-name><meta-value>Johnson Q, Syce J, Nell H, Rudeen K, Folk WR (2007) A randomized, double-blind, placebo-controlled trial of <named-content content-type="genus-species">Lessertia frutescens</named-content> in healthy adults. PLoS Clin Trials 2(4): e16. doi:<ext-link ext-link-type="doi" xlink:href="10.1371/journal.pctr.0020016">10.1371/journal.pctr.0020016</ext-link></meta-value></custom-meta><custom-meta><meta-name>trial-registry</meta-name><meta-value><named-content content-type="trial-name">www.clinicaltrials.gov</named-content><named-content content-type="trial-number">NCT00376415</named-content><named-content content-type="trial-url">http://www.clinicaltrials.gov/ct/gui/show/NCT00376415?order=1</named-content></meta-value></custom-meta><custom-meta><meta-name>trial-phase</meta-name><meta-value>I</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title><offsets xml_i="12762" xml_f="12774" txt_i="6456" txt_f="6468">INTRODUCTION</offsets></title><p><offsets xml_i="12785" xml_f="13181" txt_i="6469" txt_f="6865">The vast majority of people in South Africa use traditional medicines, which the government has recently recognized as an integral part of the public health system. However, there have been no scientific studies of traditional medicines to evaluate their safety and efficacy, nor is there agreement as to the ethical and regulatory norms for the conduct of clinical trials of such phytotherapies.</offsets></p><p><offsets xml_i="13188" xml_f="13265" txt_i="6866" txt_f="6943">Infusions and stem and leaf decoctions of the indigenous South African plant </offsets><named-content content-type="genus-species"><offsets xml_i="13309" xml_f="13329" txt_i="6943" txt_f="6963">Lessertia frutescens</offsets></named-content><offsets xml_i="13345" xml_f="13387" txt_i="6963" txt_f="7001"> (L.) Goldblatt &amp; J. C. Manning (syn. </offsets><italic><offsets xml_i="13395" xml_f="13430" txt_i="7001" txt_f="7036">Sutherlandia frutescens [L.] R. Br.</offsets></italic><offsets xml_i="13439" xml_f="13458" txt_i="7036" txt_f="7055">), commonly called </offsets><italic><offsets xml_i="13466" xml_f="13479" txt_i="7055" txt_f="7068">Sutherlandia,</offsets></italic><offsets xml_i="13488" xml_f="13795" txt_i="7068" txt_f="7375"> have been widely used in South Africa as traditional medicines since they were first adopted by the Khoi, San, and Nama peoples. In fact, the traditional Tswana name “Phetola” means “it changes” many illnesses into favorable outcomes. More specifically, it is taken to treat symptoms associated with AIDS [</offsets><xref rid="pctr-0020016-b001" ref-type="bibr"><offsets xml_i="13841" xml_f="13842" txt_i="7375" txt_f="7376">1</offsets></xref><offsets xml_i="13849" xml_f="13850" txt_i="7376" txt_f="7377">–</offsets><xref rid="pctr-0020016-b003" ref-type="bibr"><offsets xml_i="13896" xml_f="13897" txt_i="7377" txt_f="7378">3</offsets></xref><offsets xml_i="13904" xml_f="13929" txt_i="7378" txt_f="7403">], and to combat cancer [</offsets><xref rid="pctr-0020016-b004" ref-type="bibr"><offsets xml_i="13975" xml_f="13976" txt_i="7403" txt_f="7404">4</offsets></xref><offsets xml_i="13983" xml_f="13984" txt_i="7404" txt_f="7405">–</offsets><xref rid="pctr-0020016-b006" ref-type="bibr"><offsets xml_i="14030" xml_f="14031" txt_i="7405" txt_f="7406">6</offsets></xref><offsets xml_i="14038" xml_f="14053" txt_i="7406" txt_f="7421">], infections [</offsets><xref rid="pctr-0020016-b007" ref-type="bibr"><offsets xml_i="14099" xml_f="14100" txt_i="7421" txt_f="7422">7</offsets></xref><offsets xml_i="14107" xml_f="14124" txt_i="7422" txt_f="7439">], inflammation [</offsets><xref rid="pctr-0020016-b008" ref-type="bibr"><offsets xml_i="14170" xml_f="14171" txt_i="7439" txt_f="7440">8</offsets></xref><offsets xml_i="14178" xml_f="14179" txt_i="7440" txt_f="7441">,</offsets><xref rid="pctr-0020016-b009" ref-type="bibr"><offsets xml_i="14225" xml_f="14226" txt_i="7441" txt_f="7442">9</offsets></xref><offsets xml_i="14233" xml_f="14248" txt_i="7442" txt_f="7457">], and stress [</offsets><xref rid="pctr-0020016-b010" ref-type="bibr"><offsets xml_i="14294" xml_f="14296" txt_i="7457" txt_f="7459">10</offsets></xref><offsets xml_i="14303" xml_f="14305" txt_i="7459" txt_f="7461">].</offsets></p><p><offsets xml_i="14312" xml_f="14338" txt_i="7462" txt_f="7488">A study in vervet monkeys </offsets><italic><offsets xml_i="14346" xml_f="14368" txt_i="7488" txt_f="7510">(Chlorocebus aethiops)</offsets></italic><offsets xml_i="14377" xml_f="14429" txt_i="7510" txt_f="7562"> found that up to nine times the advertised dose of </offsets><italic><offsets xml_i="14437" xml_f="14449" txt_i="7562" txt_f="7574">Sutherlandia</offsets></italic><offsets xml_i="14458" xml_f="14605" txt_i="7574" txt_f="7721"> (81 mg/kg body weight per day for 3 mo) resulted in no significant changes to relevant haematological, biochemical, and physiological parameters [</offsets><xref rid="pctr-0020016-b011" ref-type="bibr"><offsets xml_i="14651" xml_f="14653" txt_i="7721" txt_f="7723">11</offsets></xref><offsets xml_i="14660" xml_f="14959" txt_i="7723" txt_f="8022">]. The present investigation aimed to (a) monitor adverse events in healthy human participants; (b) monitor changes in physical, vital, blood, and biomarker indices; (c) contribute to establishing procedures for the ethical and scientific conduct of a human clinical trial of a traditional medicine.</offsets></p><sec id="s1a"><title><offsets xml_i="14984" xml_f="14993" txt_i="8023" txt_f="8032">Objective</offsets></title><p><offsets xml_i="15004" xml_f="15064" txt_i="8033" txt_f="8093">Our objective was to conduct a pilot study of the safety of </offsets><italic><offsets xml_i="15072" xml_f="15084" txt_i="8093" txt_f="8105">Sutherlandia</offsets></italic><offsets xml_i="15093" xml_f="15133" txt_i="8105" txt_f="8145"> leaf powder capsules in healthy adults.</offsets></p></sec></sec><sec id="s2"><title><offsets xml_i="15169" xml_f="15176" txt_i="8148" txt_f="8155">METHODS</offsets></title><sec id="s2a"><title><offsets xml_i="15205" xml_f="15217" txt_i="8156" txt_f="8168">Participants</offsets></title><p><offsets xml_i="15228" xml_f="16561" txt_i="8169" txt_f="9499">The study took place at Tiervlei Trial Centre, Karl Bremer Hospital, Bellville, South Africa. Forty-one adults were recruited and screened from August to September 2004. Participant inclusion criteria were body weights within 25% of an appropriate body mass index and no significant diseases or clinically significant abnormal laboratory values during screening. Participants had no history of allergic conditions (asthma, urticaria, eczema; autoimmune disorders), systemic lupus erythematosis; dyspepsia, gastric ulcer, or duodenal ulcer; or psychiatric disorders. Their 12-lead ECGs had no significant abnormalities. They were not on regular medical treatment, and did not take any medication 14 d prior to the study. They had a smoking history or less than ten pack-years, no recent history of alcoholism (&gt;2 y) or consumption of alcohol within 48 h of receiving study medication, and did not use any recreational drugs or have a history of drug addiction. Female participants were tested and found not to be pregnant, and all women were requested to use appropriate means of contraception. Participants who did not meet the aforementioned criteria were excluded from the study. All participants were able to communicate effectively with study personnel, were informed of the nature of the study, and provided informed consent.</offsets></p><p><offsets xml_i="16568" xml_f="18149" txt_i="9500" txt_f="11081">The study protocol (protocol number M03/11/06) was approved by the Stellenbosch University Institutional Research Board (IRB) on 10 March 2004 with assurances to provide amendments to the board regarding any changes to the protocol, report unexpected serious adverse events or adverse drug reactions suspected to be related to the study drug, notify in the event the study was discontinued, adhere to the principles of informed consent for all participants (providing patient information and consents in English, Afrikaans, and Xhosa languages), and provide progress reports twice each year during the trial. The protocol was also approved by the South African Medicine Control Council (MCC protocol number TICIPS001) on 20 July 2004, with assurances that sufficient amounts of product of assayed quality to conduct the trial was available, and to notify the MCC of any severe adverse events or if the trial was discontinued, provide progress reports during the trial, and to administer the medicine under the direction of an authorized trialist. To ensure medical coverage for potential harm of the individuals from participation in the study trial, the trial was underwritten by a national (South African) insurance company as a requirement by both the Stellenbosch IRB and MCC. Application materials, including the protocol, were provided to the University of Missouri Health Sciences IRB, reviewed and approved on 7 April 2004 (project number 1042077) for conduct of activities in South Africa as approved by the local Stellenbosch IRB and South African MCC reviewing agencies.</offsets></p></sec><sec id="s2b"><title><offsets xml_i="18180" xml_f="18193" txt_i="11083" txt_f="11096">Interventions</offsets></title><p><offsets xml_i="18204" xml_f="18315" txt_i="11097" txt_f="11208">Of the 41 participants, 25 who met the trial criteria were enrolled in the study and randomized to two groups (</offsets><xref ref-type="fig" rid="pctr-0020016-g001"><offsets xml_i="18360" xml_f="18368" txt_i="11208" txt_f="11216">Figure 1</offsets></xref><offsets xml_i="18375" xml_f="18450" txt_i="11216" txt_f="11291">): 12 randomized to a treatment arm consumed capsules containing 400 mg of </offsets><italic><offsets xml_i="18458" xml_f="18470" txt_i="11291" txt_f="11303">Sutherlandia</offsets></italic><offsets xml_i="18479" xml_f="19220" txt_i="11303" txt_f="12044"> leaf powder (400 mg of plant material per capsule; 600 μg of canavanine per capsule) twice daily (800 mg/day) and 13 randomized to the control arm consumed a placebo capsule of lettuce leaf powder twice per day. The treatment and placebo materials were placed in rapidly releasing capsules, and these were assessed pharmaceutically for content uniformity, stability, and release characteristics as well as microbial, heavy metal, and pesticide contamination, before the products were packaged and used in the 3-mo clinical trial. Furthermore, the clinical trial conformed to MCC and NCCAM guidance on the quality of biologically active ingredients and placebo materials used in complementary, alternative, and traditional medicine products.</offsets></p><fig id="pctr-0020016-g001" position="float"><label><offsets xml_i="19276" xml_f="19284" txt_i="12045" txt_f="12053">Figure 1</offsets></label><caption><title><offsets xml_i="19308" xml_f="19321" txt_i="12053" txt_f="12066">Trial Profile</offsets></title><p><offsets xml_i="19332" xml_f="19349" txt_i="12067" txt_f="12084">CONSORT flowchart</offsets></p></caption><graphic xlink:href="pctr.0020016.g001"></graphic></fig></sec><sec id="s2c"><title><offsets xml_i="19446" xml_f="19454" txt_i="12086" txt_f="12094">Outcomes</offsets></title><p><offsets xml_i="19465" xml_f="19589" txt_i="12095" txt_f="12219">The primary endpoints of this study were incidence (number) and type of adverse events recorded during the treatment period.</offsets></p><p><offsets xml_i="19596" xml_f="19842" txt_i="12220" txt_f="12466">The secondary endpoints were: (a) changes in weight, blood pressure, heart rate, respiratory rate, body temperature from baseline to end of treatment; and (b) changes in haematological and biochemical parameters from baseline to end of treatment.</offsets></p></sec><sec id="s2d"><title><offsets xml_i="19873" xml_f="19884" txt_i="12468" txt_f="12479">Sample Size</offsets></title><p><offsets xml_i="19895" xml_f="20586" txt_i="12480" txt_f="13171">In the absence of previous data, a convenience sample size of about 12 participants per treatment group was chosen for this first study of a South African traditional medicine in healthy humans. This relatively small sample size is a limitation of the study. It does, however, give sufficient power to detect an effect size of 1.20 with 80% power based on doing a two-sample t-test at a significance level of 0.05 with a two-sided alternative. Effect size is defined as the difference in group means divided by the standard deviation of the response variable under consideration. This applies to numeric variables. For categorical variables, the numbers are too small to do meaningful tests.</offsets></p></sec><sec id="s2e"><title><offsets xml_i="20617" xml_f="20651" txt_i="13173" txt_f="13207">Randomization: Sequence Generation</offsets></title><p><offsets xml_i="20662" xml_f="20860" txt_i="13208" txt_f="13406">To achieve randomization, a list of random numbers allocating to the two treatments (A, active treatment; B, placebo) a maximum of 13 participants per group was generated using a GraphPad Software (</offsets><ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com"><offsets xml_i="20927" xml_f="20950" txt_i="13406" txt_f="13429">http://www.graphpad.com</offsets></ext-link><offsets xml_i="20961" xml_f="21358" txt_i="13429" txt_f="13826">) calculator option. For each number, a 3-mo supply of the relevant treatment (active or placebo) was labeled with that particular number. The randomized number generation and labeling of the treatments were performed by one person at the School of Pharmacy, University of the Western Cape, and the labeled materials (for 3-mo dosing of each of 25 participants) shipped to the clinical trial site.</offsets></p></sec><sec id="s2f"><title><offsets xml_i="21389" xml_f="21426" txt_i="13828" txt_f="13865">Randomization: Allocation Concealment</offsets></title><p><offsets xml_i="21437" xml_f="21548" txt_i="13866" txt_f="13977">The person generating the randomized list also did the labeling of the treatments and kept the randomized list.</offsets></p></sec><sec id="s2g"><title><offsets xml_i="21579" xml_f="21608" txt_i="13979" txt_f="14008">Randomization: Implementation</offsets></title><p><offsets xml_i="21619" xml_f="22010" txt_i="14009" txt_f="14400">At the trial site, participants were sequentially allocated to the treatments in the order in which they were recruited, i.e., the first person who qualified for inclusion was given treatment number 1, the second one treatment number 2, and so on. When allocated, the participant ID number was added to the label details on the capsule containers. The clinician on site made this allocation.</offsets></p></sec><sec id="s2h"><title><offsets xml_i="22041" xml_f="22049" txt_i="14402" txt_f="14410">Blinding</offsets></title><p><offsets xml_i="22060" xml_f="22745" txt_i="14411" txt_f="15096">The placebo and treatment capsules containing plant materials were packed in identical nontransparent containers. Neither the participants nor the clinicians knew which treatment they received or dispensed. The data collected were retrieved from the case report form by another researcher, at the South African Herbal Science and Medicine Institute, the University of the Western Cape, who loaded it into a database. Once accuracy of the data was confirmed (i.e., clean file status), the database was forwarded to the statisticians who, only at this time, were supplied with the randomized treatment list. The statisticians then identified the participants allocated to each treatment.</offsets></p></sec><sec id="s2i"><title><offsets xml_i="22776" xml_f="22818" txt_i="15098" txt_f="15140">Laboratory Measurements and Blood Sampling</offsets></title><p><offsets xml_i="22829" xml_f="23183" txt_i="15141" txt_f="15495">Participants were provided with diaries in which to self-report all adverse events for the duration of the trial. Participants were screened (at the baseline visit, participants were screened for physical, vital, haematological, biochemical, and endocrine indices), randomized (at postbaseline, participants were provided with capsules containing either </offsets><italic><offsets xml_i="23191" xml_f="23203" txt_i="15495" txt_f="15507">Sutherlandia</offsets></italic><offsets xml_i="23212" xml_f="23804" txt_i="15507" txt_f="16099"> or placebo material), treated, and assessed (at months 1–3) for the same parameters that were determined at the baseline visit. Participants were subjected to a physical examination (weight, blood pressure, heart rate, respiratory rate, body temperature, and ECG measurement), and they provided blood samples for haematology, endocrine, and biochemistry analysis by standard laboratory methods. The plasma samples of trial participants were analyzed for canavanine by liquid chromatographic separation and mass spectrophotometric determination, with a Waters API Q-TOF Ultima LCMSMS system (</offsets><ext-link ext-link-type="uri" xlink:href="http://www.waters.com"><offsets xml_i="23869" xml_f="23890" txt_i="16099" txt_f="16120">http://www.waters.com</offsets></ext-link><offsets xml_i="23901" xml_f="23965" txt_i="16120" txt_f="16184">). Other biochemical variables were measured with Abbott AxSYM (</offsets><ext-link ext-link-type="uri" xlink:href="http://www.abbottdiagnostics.com"><offsets xml_i="24041" xml_f="24073" txt_i="16184" txt_f="16216">http://www.abbottdiagnostics.com</offsets></ext-link><offsets xml_i="24084" xml_f="24115" txt_i="16216" txt_f="16247">) and Beckman Coulter CX9 ALX (</offsets><ext-link ext-link-type="uri" xlink:href="http://www.beckmancoulter.com"><offsets xml_i="24188" xml_f="24217" txt_i="16247" txt_f="16276">http://www.beckmancoulter.com</offsets></ext-link><offsets xml_i="24228" xml_f="24431" txt_i="16276" txt_f="16479">) systems, respectively. All haematology indices were measured using a Beckman Coulter Gen-S system, while CD3, CD4, and CD8 counts were determined by flow cytometry, with a Beckman Coulter EPICS system.</offsets></p></sec><sec id="s2j"><title><offsets xml_i="24462" xml_f="24481" txt_i="16481" txt_f="16500">Statistical Methods</offsets></title><p><offsets xml_i="24492" xml_f="25243" txt_i="16501" txt_f="17252">Analysis for adverse events was done descriptively. With the small number of participants in each group the power to detect all but very large differences is relatively small. Doing Chi-square tests and finding that results are insignificant would not be very informative. Consequently, the number of participants who experienced adverse events of different types is given. Some participants reported the same adverse event (e.g., “increased appetite”) on more than one occasion. For this reason we counted the number of participants who experienced an adverse event at least once for the summary rather than giving a count of the number of times the event was reported. Counts, proportions, and 95% confidence intervals for the proportions are given.</offsets></p><p><offsets xml_i="25250" xml_f="25604" txt_i="17253" txt_f="17607">For the statistical analysis of all the haematology and biochemistry parameters, a repeated measures ANOVA model was used, with the treatment group as one factor and PREPOST, an indicator for the post-treatment measurement, as a factor with repeated measures. The interaction term (treatment by PREPOST) measures the difference between the comparison of </offsets><italic><offsets xml_i="25612" xml_f="25624" txt_i="17607" txt_f="17619">Sutherlandia</offsets></italic><offsets xml_i="25633" xml_f="25708" txt_i="17619" txt_f="17694"> (treatment) versus placebo groups at PRE (baseline) and the comparison of </offsets><italic><offsets xml_i="25716" xml_f="25728" txt_i="17694" txt_f="17706">Sutherlandia</offsets></italic><offsets xml_i="25737" xml_f="25927" txt_i="17706" txt_f="17896"> versus placebo groups at POST (months 1–3: treatment). The Kenward-Roger denominator degrees of freedom method was used for the fixed effects testing, whilst Proc Mixed in SAS Version 9.1 (</offsets><ext-link ext-link-type="uri" xlink:href="http://www.sas.com"><offsets xml_i="25989" xml_f="26007" txt_i="17896" txt_f="17914">http://www.sas.com</offsets></ext-link><offsets xml_i="26018" xml_f="26511" txt_i="17914" txt_f="18407">) was used for the modelling. Least squares means were used to estimate treatment effects at the combined visits 3–5 based on the mean response models. Comparisons between pretreatment and post-treatment were obtained for all indices in the study. Statistical significance for these outcomes was set at the 5% level. Again, in the spirit of being conservative, adjustments for multiple tests (such as the Bonferroni adjustment) were not made. This most likely resulted in some false positives.</offsets></p></sec></sec><sec id="s3"><title><offsets xml_i="26547" xml_f="26554" txt_i="18410" txt_f="18417">RESULTS</offsets></title><sec id="s3a"><title><offsets xml_i="26583" xml_f="26615" txt_i="18418" txt_f="18450">Recruitment and Participant Flow</offsets></title><p><offsets xml_i="26626" xml_f="27032" txt_i="18451" txt_f="18857">A total of 41 participants were recruited and screened (visit 1: baseline physical, vital, and blood indices) between August and September 2004. Of these, 25 consented, met the trial criteria, and were subjected to a blood draw for haematology, endocrine and biochemistry analysis, to establish baseline (pretreatment) values. Thereafter, they were randomized (postbaseline) to receive treatment capsules (</offsets><italic><offsets xml_i="27040" xml_f="27041" txt_i="18857" txt_f="18858">n</offsets></italic><offsets xml_i="27050" xml_f="27086" txt_i="18858" txt_f="18894"> = 12) or placebo control capsules (</offsets><italic><offsets xml_i="27094" xml_f="27095" txt_i="18894" txt_f="18895">n</offsets></italic><offsets xml_i="27104" xml_f="27606" txt_i="18895" txt_f="19397"> = 13) that contained a small amount of dried lettuce leaves twice per day, treated, and assessed (at months 1–3). Participants were given a diary to record the times they took their trial medication, adverse effects they may have experienced, and other medications they may have taken over the course of the trial. During the three-month study period, one adult was lost to follow-up and another withdrew from the treatment group. In the placebo group, two adults withdrew and another became pregnant.</offsets></p></sec><sec id="s3b"><title><offsets xml_i="27637" xml_f="27650" txt_i="19399" txt_f="19412">Baseline Data</offsets></title><p><offsets xml_i="27661" xml_f="27794" txt_i="19413" txt_f="19546">Baseline data for vital, physical, haematological, biochemical, and endocrine indices were similar for the 25 eligible participants (</offsets><xref ref-type="table" rid="pctr-0020016-t001"><offsets xml_i="27841" xml_f="27848" txt_i="19546" txt_f="19553">Table 1</offsets></xref><offsets xml_i="27855" xml_f="27857" txt_i="19553" txt_f="19555">).</offsets></p><table-wrap id="pctr-0020016-t001" content-type="1col" position="float"><label><offsets xml_i="27940" xml_f="27947" txt_i="19556" txt_f="19563">Table 1</offsets></label><caption><p><offsets xml_i="27967" xml_f="28031" txt_i="19563" txt_f="19627">Baseline Data (Mean ± Standard Deviation) for Trial Participants</offsets></p></caption><graphic xlink:href="pctr.0020016.t001"></graphic></table-wrap></sec><sec id="s3c"><title><offsets xml_i="28135" xml_f="28158" txt_i="19629" txt_f="19652">Outcomes and Estimation</offsets></title><p><offsets xml_i="28169" xml_f="28833" txt_i="19653" txt_f="20317">In summarising the adverse events reported by participants at any of the follow-up visits, we note that one individual in the placebo group was only in the study for 5 d, with no follow-up data. That individual is not included in the summary given so there are 12 participants in each group. While the number of days in the study did vary from participant to participant, the cumulative number of exposure days for the two groups were similar, with 957 and 972 total days for the treatment and placebo groups, respectively. A count was made of the number of participants who reported a particular type of adverse event at least once. The results are summarized in </offsets><xref ref-type="table" rid="pctr-0020016-t002"><offsets xml_i="28880" xml_f="28887" txt_i="20317" txt_f="20324">Table 2</offsets></xref><offsets xml_i="28894" xml_f="29388" txt_i="20324" txt_f="20818">, where, in addition to the counts, the percentage of participants (out of 12) who experienced the event at least once is given along with an exact 95% confidence interval estimate of the proportion. As shown in the table, the types of events include cardiovascular (e.g., palpitations, nosebleeds), central nervous system (CNS; e.g., headaches, nervousness, insomnia, dizziness), gastrointestinal tract (GIT), infection, allergy, appetite, malaise, or general adverse events. The last line of </offsets><xref ref-type="table" rid="pctr-0020016-t002"><offsets xml_i="29435" xml_f="29442" txt_i="20818" txt_f="20825">Table 2</offsets></xref><offsets xml_i="29449" xml_f="29658" txt_i="20825" txt_f="21034"> gives the number of participants who reported any adverse event at any time. We would point out that with the small number of participants, it is unlikely that rare adverse events would be seen in this study.</offsets></p><table-wrap id="pctr-0020016-t002" content-type="2col" position="float"><label><offsets xml_i="29741" xml_f="29748" txt_i="21035" txt_f="21042">Table 2</offsets></label><caption><p><offsets xml_i="29768" xml_f="29929" txt_i="21042" txt_f="21203">Counts, Percentages, Group Differences and 95% Confidence Interval Estimates of Proportion of Subjects Reporting at Least One Adverse Event of the Type Described</offsets></p></caption><graphic xlink:href="pctr.0020016.t002"></graphic></table-wrap><p><offsets xml_i="30009" xml_f="30010" txt_i="21204" txt_f="21205">
</offsets><xref ref-type="table" rid="pctr-0020016-t003"><offsets xml_i="30057" xml_f="30064" txt_i="21205" txt_f="21212">Table 3</offsets></xref><offsets xml_i="30071" xml_f="30240" txt_i="21212" txt_f="21381"> provides a list of the vital, physical, haematological, biochemical, and endocrine data that were not significantly different between the treatment and placebo groups (</offsets><italic><offsets xml_i="30248" xml_f="30249" txt_i="21381" txt_f="21382">p</offsets></italic><offsets xml_i="30258" xml_f="30270" txt_i="21382" txt_f="21391"> &gt; 0.05).</offsets></p><table-wrap id="pctr-0020016-t003" content-type="1col" position="float"><label><offsets xml_i="30353" xml_f="30360" txt_i="21392" txt_f="21399">Table 3</offsets></label><caption><p><offsets xml_i="30380" xml_f="30530" txt_i="21399" txt_f="21549">Vital, Physical, Haematological, Biochemical, and Endocrine Endpoints that Were Not Significantly Different between the Treatment and Placebo Groups (</offsets><italic><offsets xml_i="30538" xml_f="30539" txt_i="21549" txt_f="21550">p</offsets></italic><offsets xml_i="30548" xml_f="30613" txt_i="21550" txt_f="21612"> &gt; 0.05), and within the Normal Physiological Range for Humans</offsets></p></caption><graphic xlink:href="pctr.0020016.t003"></graphic></table-wrap><p><offsets xml_i="30693" xml_f="30880" txt_i="21613" txt_f="21800">Most of the vital and physical, haematological, biochemical, and endocrine endpoints that were measured were within the normal physiological range and not significantly different for the </offsets><italic><offsets xml_i="30888" xml_f="30900" txt_i="21800" txt_f="21812">Sutherlandia</offsets></italic><offsets xml_i="30909" xml_f="31103" txt_i="21812" txt_f="22006"> and placebo groups. These include: diastolic and systolic blood pressure (BP), electrocardiogram (ECG), heart rate, body temperature (oral), and weight and height; white cell and red cell count</offsets><bold><offsets xml_i="31109" xml_f="31110" txt_i="22006" txt_f="22007">s</offsets></bold><offsets xml_i="31117" xml_f="31775" txt_i="22007" txt_f="22665">, haemoglobin, haematocrit, mean corpuscular volume (MCV), and red cell diameter and width (RCDW); neutrophil, monocyte, lymphocyte, eosinophil, and basophil counts; CD3, CD4, CD8 counts, and CD4:CD8 ratio; sodium, potassium, and chloride; urea, creatinine, and bilirubin; alkaline phosphatase, T-glutamyl transferase, alanine transaminase, aspartate transaminase, lactate dehydrogenase, creatine kinase, plasma glucose (random), calcium and corrected calcium, magnesium, and phosphorous; free thyroxine, free tri-iodothyroxine, and TSH; and cholesterol, LDL-cholesterol, HDL-chlolesterol, and triglycerides. No canavanine was detected in any of the samples.</offsets></p><p><offsets xml_i="31782" xml_f="31783" txt_i="22666" txt_f="22667">
</offsets><xref ref-type="table" rid="pctr-0020016-t004"><offsets xml_i="31830" xml_f="31837" txt_i="22667" txt_f="22674">Table 4</offsets></xref><offsets xml_i="31844" xml_f="31961" txt_i="22674" txt_f="22791"> contains the data for the six variables that were statistically different between the treatment and placebo groups (</offsets><italic><offsets xml_i="31969" xml_f="31970" txt_i="22791" txt_f="22792">p</offsets></italic><offsets xml_i="31979" xml_f="31996" txt_i="22792" txt_f="22806"> &lt; 0.05). The </offsets><italic><offsets xml_i="32004" xml_f="32016" txt_i="22806" txt_f="22818">Sutherlandia</offsets></italic><offsets xml_i="32025" xml_f="32062" txt_i="22818" txt_f="22855"> group had a lower respiration rate (</offsets><italic><offsets xml_i="32070" xml_f="32071" txt_i="22855" txt_f="22856">p</offsets></italic><offsets xml_i="32080" xml_f="32120" txt_i="22856" txt_f="22893"> &lt; 0.04), but higher platelet count (</offsets><italic><offsets xml_i="32128" xml_f="32129" txt_i="22893" txt_f="22894">p</offsets></italic><offsets xml_i="32138" xml_f="32238" txt_i="22894" txt_f="22994"> = 0.03) than the placebo group. In relation to baseline values, mean corpuscular haemoglobin (MCH; </offsets><italic><offsets xml_i="32246" xml_f="32247" txt_i="22994" txt_f="22995">p</offsets></italic><offsets xml_i="32256" xml_f="32319" txt_i="22995" txt_f="23058"> = 0.01) and mean corpuscular haemoglobin concentration (MCHC; </offsets><italic><offsets xml_i="32327" xml_f="32328" txt_i="23058" txt_f="23059">p</offsets></italic><offsets xml_i="32337" xml_f="32372" txt_i="23059" txt_f="23094"> = 0.02) levels were lower for the </offsets><italic><offsets xml_i="32380" xml_f="32392" txt_i="23094" txt_f="23106">Sutherlandia</offsets></italic><offsets xml_i="32401" xml_f="32428" txt_i="23106" txt_f="23133"> compared to placebo group.</offsets></p><table-wrap id="pctr-0020016-t004" content-type="2col" position="float"><label><offsets xml_i="32511" xml_f="32518" txt_i="23134" txt_f="23141">Table 4</offsets></label><caption><p><offsets xml_i="32538" xml_f="32701" txt_i="23141" txt_f="23304">Vital, Physical, Haematological, and Biochemical Endpoints (Mean ± Standard Deviation) that Were Significantly Different between the Treatment and Placebo Groups (</offsets><italic><offsets xml_i="32709" xml_f="32710" txt_i="23304" txt_f="23305">p</offsets></italic><offsets xml_i="32719" xml_f="32784" txt_i="23305" txt_f="23367"> &lt; 0.05), and within the Normal Physiological Range for Humans</offsets></p></caption><graphic xlink:href="pctr.0020016.t004"></graphic></table-wrap><p><offsets xml_i="32864" xml_f="32881" txt_i="23368" txt_f="23385">In addition, the </offsets><italic><offsets xml_i="32889" xml_f="32901" txt_i="23385" txt_f="23397">Sutherlandia</offsets></italic><offsets xml_i="32910" xml_f="32943" txt_i="23397" txt_f="23430"> group had higher total protein (</offsets><italic><offsets xml_i="32951" xml_f="32952" txt_i="23430" txt_f="23431">p</offsets></italic><offsets xml_i="32961" xml_f="32990" txt_i="23431" txt_f="23460"> = 0.03) and albumin levels (</offsets><italic><offsets xml_i="32998" xml_f="32999" txt_i="23460" txt_f="23461">p</offsets></italic><offsets xml_i="33008" xml_f="33040" txt_i="23461" txt_f="23493"> = 0.03) than the placebo group.</offsets></p><p><offsets xml_i="33047" xml_f="33061" txt_i="23494" txt_f="23508">Note that the </offsets><italic><offsets xml_i="33069" xml_f="33070" txt_i="23508" txt_f="23509">p</offsets></italic><offsets xml_i="33079" xml_f="33422" txt_i="23509" txt_f="23852">-values given are for testing the significance of the group by post interaction term. This is equivalent to a test for group differences in the amount of change from pre-treatment to post-treatment. Despite these differences, all the measurements fell within the normal physiological range for these indices, and were of no clinical relevance.</offsets></p></sec></sec><sec id="s4"><title><offsets xml_i="33458" xml_f="33468" txt_i="23855" txt_f="23865">DISCUSSION</offsets></title><sec id="s4a"><title><offsets xml_i="33497" xml_f="33511" txt_i="23866" txt_f="23880">Interpretation</offsets></title><p><offsets xml_i="33522" xml_f="33642" txt_i="23881" txt_f="24001">This pilot study is the first to provide scientific information on the safety of the South African traditional medicine </offsets><italic><offsets xml_i="33650" xml_f="33678" txt_i="24001" txt_f="24029">L. frutescens (Sutherlandia)</offsets></italic><offsets xml_i="33687" xml_f="33831" txt_i="24029" txt_f="24173"> in healthy humans, and contribute to establishing rigorous and ethical procedures for conducting clinical trials on indigenous phytotherapies. </offsets><italic><offsets xml_i="33839" xml_f="33851" txt_i="24173" txt_f="24185">Sutherlandia</offsets></italic><offsets xml_i="33860" xml_f="34295" txt_i="24185" txt_f="24620"> is used for a variety of conditions, including those associated with AIDS. Analysis for adverse events was done descriptively and included: cardiovascular (palpitations, nosebleeds), CNS (headaches, nervousness, insomnia, dizziness), GIT, infection, allergy, appetite, malaise, or general adverse events. With the small number of participants, which is a limitation to the study, it is unlikely that rare adverse events would be seen.</offsets></p><p><offsets xml_i="34302" xml_f="34818" txt_i="24621" txt_f="25137">There were no significant differences in cardiovascular, CNS, GIT, infection, allergy, malaise, or general adverse events between the treatment and the placebo groups. Whilst participants in the treatment group experienced more events related to appetite, the constraints of the investigation related to limited sample size precludes firm conclusions from being drawn about these preliminary data or any speculation related to mechanisms of action. It is nonetheless interesting to have observed this outcome, since </offsets><italic><offsets xml_i="34826" xml_f="34838" txt_i="25137" txt_f="25149">Sutherlandia</offsets></italic><offsets xml_i="34847" xml_f="34948" txt_i="25149" txt_f="25250"> is purported to prevent wasting, and is in contrast to the report that cachectic patients consuming </offsets><italic><offsets xml_i="34956" xml_f="34968" txt_i="25250" txt_f="25262">Sutherlandia</offsets></italic><offsets xml_i="34977" xml_f="35060" txt_i="25262" txt_f="25345"> exhibited side effects such as diarrhea, mild diuresis, dry mouth, and dizziness [</offsets><xref rid="pctr-0020016-b012" ref-type="bibr"><offsets xml_i="35106" xml_f="35108" txt_i="25345" txt_f="25347">12</offsets></xref><offsets xml_i="35115" xml_f="35117" txt_i="25347" txt_f="25349">].</offsets></p><p><offsets xml_i="35124" xml_f="35660" txt_i="25350" txt_f="25886">There were no significant differences between the treatment group and placebo group for most of the vital, physical, haematological, biochemical, or endocrine parameters. In adjusting for baseline values, the treatment group had higher MCH, MCHC, platelet, total protein and albumin count, and lower respiration rate compared to the placebo group, but these differences were not clinically significant. Whilst the latter outcome is noted, we do not have any dose-escalation or pharmacokinetic data from this pilot study, in relation to </offsets><italic><offsets xml_i="35668" xml_f="35680" txt_i="25886" txt_f="25898">Sutherlandia</offsets></italic><offsets xml_i="35689" xml_f="35821" txt_i="25898" txt_f="26030"> and its effect on vital, physical, haematological, biochemical, and endocrine indices, which is a limitation of this investigation.</offsets></p></sec><sec id="s4b"><title><offsets xml_i="35852" xml_f="35868" txt_i="26032" txt_f="26048">Generalizability</offsets></title><p><offsets xml_i="35879" xml_f="35880" txt_i="26049" txt_f="26050">
</offsets><italic><offsets xml_i="35888" xml_f="35900" txt_i="26050" txt_f="26062">Sutherlandia</offsets></italic><offsets xml_i="35909" xml_f="36213" txt_i="26062" txt_f="26366"> in the amount studied (800 mg/day) is widely advertised as being safe and is undoubtedly consumed by many, and it was tolerated by the limited number of healthy adults in this pilot study. Nevertheless, additional studies are warranted to assess the safety and efficacy of this and other phytotherapies.</offsets></p><p><offsets xml_i="36220" xml_f="36418" txt_i="26367" txt_f="26565">This study has established a precedent for the ethical and scientifically rigorous evaluation of indigenous medicines used by the public, and it is hoped that additional studies will quickly follow.</offsets></p></sec><sec id="s4c"><title><offsets xml_i="36449" xml_f="36465" txt_i="26567" txt_f="26583">Overall Evidence</offsets></title><p><offsets xml_i="36476" xml_f="36560" txt_i="26584" txt_f="26668">Until now, no human studies have been conducted to assess the safety or efficacy of </offsets><italic><offsets xml_i="36568" xml_f="36596" txt_i="26668" txt_f="26696">L. frutescens (Sutherlandia)</offsets></italic><offsets xml_i="36605" xml_f="36709" txt_i="26696" txt_f="26800"> with its claimed benefits ascribed to constituents including pinitol, γ-amino butyric acid (GABA), and </offsets><sc><offsets xml_i="36713" xml_f="36714" txt_i="26800" txt_f="26801">L</offsets></sc><offsets xml_i="36719" xml_f="36732" txt_i="26801" txt_f="26814">-canavanine [</offsets><xref rid="pctr-0020016-b013" ref-type="bibr"><offsets xml_i="36778" xml_f="36780" txt_i="26814" txt_f="26816">13</offsets></xref><offsets xml_i="36787" xml_f="36788" txt_i="26816" txt_f="26817">,</offsets><xref rid="pctr-0020016-b014" ref-type="bibr"><offsets xml_i="36834" xml_f="36836" txt_i="26817" txt_f="26819">14</offsets></xref><offsets xml_i="36843" xml_f="36990" txt_i="26819" txt_f="26966">]. It is not known if these constituents work in isolation or in unison. GABA is an inhibitory neurotransmitter present in appreciable quantities [</offsets><xref rid="pctr-0020016-b014" ref-type="bibr"><offsets xml_i="37036" xml_f="37038" txt_i="26966" txt_f="26968">14</offsets></xref><offsets xml_i="37045" xml_f="37181" txt_i="26968" txt_f="27104">], and it may potentially have beneficial effects on stress, anxiety, and depression, which adversely affect the course of HIV disease [</offsets><xref rid="pctr-0020016-b015" ref-type="bibr"><offsets xml_i="37227" xml_f="37229" txt_i="27104" txt_f="27106">15</offsets></xref><offsets xml_i="37236" xml_f="37262" txt_i="27106" txt_f="27132">]. Canavanine is a potent </offsets><sc><offsets xml_i="37266" xml_f="37267" txt_i="27132" txt_f="27133">L</offsets></sc><offsets xml_i="37272" xml_f="37359" txt_i="27133" txt_f="27220">-arginine antagonist, with antiviral, antifungal, antibacterial, and anticancer value [</offsets><xref rid="pctr-0020016-b016" ref-type="bibr"><offsets xml_i="37405" xml_f="37407" txt_i="27220" txt_f="27222">16</offsets></xref><offsets xml_i="37414" xml_f="37415" txt_i="27222" txt_f="27223">–</offsets><xref rid="pctr-0020016-b019" ref-type="bibr"><offsets xml_i="37461" xml_f="37463" txt_i="27223" txt_f="27225">19</offsets></xref><offsets xml_i="37470" xml_f="37724" txt_i="27225" txt_f="27479">]. Concerns have been raised over the possible induction by canavanine of autoimmune diseases (such as systemic lupus erythematosis), which is thought only to occur at very high doses in predisposed individuals or in the presence of low arginine levels [</offsets><xref rid="pctr-0020016-b020" ref-type="bibr"><offsets xml_i="37770" xml_f="37772" txt_i="27479" txt_f="27481">20</offsets></xref><offsets xml_i="37779" xml_f="38017" txt_i="27481" txt_f="27719">]. However, canavanine was not detected in the plasma of the trial participants, perhaps because of the dosage and its metabolism, and possible biotransformation into another molecular entity through the P450 system, which is affected by </offsets><named-content content-type="genus-species"><offsets xml_i="38061" xml_f="38074" txt_i="27719" txt_f="27732">L. frutescens</offsets></named-content><offsets xml_i="38090" xml_f="38092" txt_i="27732" txt_f="27734"> [</offsets><xref rid="pctr-0020016-b021" ref-type="bibr"><offsets xml_i="38138" xml_f="38140" txt_i="27734" txt_f="27736">21</offsets></xref><offsets xml_i="38147" xml_f="38149" txt_i="27736" txt_f="27738">].</offsets></p><p><offsets xml_i="38156" xml_f="38367" txt_i="27739" txt_f="27950">A recent Cochrane review of nine randomised placebo-controlled trials involving 499 individuals with HIV infection and AIDS, wherein eight different Chinese herbal medicines were tested, was recently completed [</offsets><xref rid="pctr-0020016-b022" ref-type="bibr"><offsets xml_i="38413" xml_f="38415" txt_i="27950" txt_f="27952">22</offsets></xref><offsets xml_i="38422" xml_f="38817" txt_i="27952" txt_f="28347">]. Evidence for the effect of the eight herbal medicines identified in the review for treatment of HIV infection and AIDS was not compelling. Moreover, the review concluded that a need exists for larger and more rigorously designed trials. To our knowledge, this is the first report of a double-blind, randomized, placebo-controlled study assessing the safety of the African indigenous medicine </offsets><italic><offsets xml_i="38825" xml_f="38837" txt_i="28347" txt_f="28359">Sutherlandia</offsets></italic><offsets xml_i="38846" xml_f="39050" txt_i="28359" txt_f="28563">. This investigation provides a vital step for better understanding the clinical value of traditional phytotherapies in healthy humans. Given that this African indigenous medicine is so extensively used [</offsets><xref rid="pctr-0020016-b023" ref-type="bibr"><offsets xml_i="39096" xml_f="39098" txt_i="28563" txt_f="28565">23</offsets></xref><offsets xml_i="39105" xml_f="39305" txt_i="28565" txt_f="28765">], and is taken by many for the treatment of a variety of conditions including those associated with HIV and AIDS, additional safety and efficacy trials are warranted in the interest of public health.</offsets></p></sec></sec><sec sec-type="supplementary-material" id="s5"><title><offsets xml_i="39375" xml_f="39397" txt_i="28768" txt_f="28790">SUPPORTING INFORMATION</offsets></title><supplementary-material content-type="local-data" id="pctr-0020016-sd001"><label><offsets xml_i="39486" xml_f="39503" txt_i="28791" txt_f="28808">CONSORT Checklist</offsets></label><caption><p><offsets xml_i="39523" xml_f="39534" txt_i="28808" txt_f="28819">(43 KB DOC)</offsets></p></caption><media xlink:href="pctr.0020016.sd001.doc"><caption><p><offsets xml_i="39603" xml_f="39639" txt_i="28820" txt_f="28856">Click here for additional data file.</offsets></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pctr-0020016-sd002"><label><offsets xml_i="39767" xml_f="39781" txt_i="28857" txt_f="28871">Trial Protocol</offsets></label><caption><p><offsets xml_i="39801" xml_f="39813" txt_i="28871" txt_f="28883">(357 KB DOC)</offsets></p></caption><media xlink:href="pctr.0020016.sd002.doc"><caption><p><offsets xml_i="39882" xml_f="39918" txt_i="28884" txt_f="28920">Click here for additional data file.</offsets></p></caption></media></supplementary-material></sec></body><back><ack><p>We particularly thank Dr. Wilfred Mabusela for analytical advice and Dr. Joanita Adams (University of the Western Cape), for retrieving data from the case report forms and loading it into a database. We also appreciate the biostatistical service that we received from colleagues at the Medical Research Council, South Africa, Prof. (Emeritus) Richard Madsen (University Missouri, Columbia) and Prof. Karen Williams (University Missouri, Kansas City). We are also grateful to Dr. Jim Miller from the Missouri Botanical Garden for botanical advice, Dr. Doug Wilson (Edendale Hospital, Kwazulu-Natal), Prof. Gary Maartens (Groote Schuur Hospital, Cape Town), and Prof. Kathy Goggin (University Missouri-Kansas City), for commenting on the manuscript. We value the contribution from members of The International Center for Indigenous Phytotherapies (TICIPS) to the design of the study and the efforts of staff at the Tiervlei Trial Centre, Karl Bremer Hospital, Western Cape. Furthermore, we appreciate all the advice that we have received from Prof. Nceba Gqaleni, Traditional Dr. Bongi Gwala, and Traditional Dr. Queen Ntuli, from the Nelson Mandela Medical School at the University of Kwazulu-Natal, as well as the contribution of Prof. Peter Eagles from the University of the Western Cape.</p></ack><fn-group><fn id="n103" fn-type="COI-statement"><p>
<bold>Competing Interests:</bold> The authors have declared that no competing interests exist.</p></fn><fn id="n101" fn-type="financial-disclosure"><p>
<bold>Funding:</bold> This study was made possible by funds from the National Center for Complementary and Alternative Medicine (NCCAM) and Fogarty International Centre (FIC) (Grant R21AT001944), at the National Institutes of Health (NIH). NCCAM and FIC had no role in the study design, collection, analysis and interpretation of data, writing of the paper, or decision to submit it for publication.</p></fn></fn-group><sec id="s6a"><title>Author Contributions</title><p>QJ, JS, KR, and WRF made primary contributions to the design and conduct of the study, analysis and interpretation of results, and preparation of the manuscript. HN conducted and controlled the quality of the trial and contributed to the study results.</p></sec><glossary><title>Abbreviations</title><def-list><def-item><term>CNS</term><def><p>central nervous system</p></def></def-item><def-item><term>GIT</term><def><p>gastrointestinal tract</p></def></def-item><def-item><term>MCH</term><def><p>mean corpuscular haemoglobin</p></def></def-item><def-item><term>MCHC</term><def><p>mean corpuscular haemoglobin concentration</p></def></def-item><def-item><term>MCV</term><def><p>mean corpuscular volume</p></def></def-item><def-item><term>RCDW</term><def><p>red cell diameter and width</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="pctr-0020016-b001"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mills</surname><given-names>E</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Kanfer</surname><given-names>I</given-names></name></person-group>
<year>2005</year>
<article-title>Traditional African medicine in the treatment of HIV</article-title>
<source>Lancet Infect Dis</source>
<volume>5</volume>
<fpage>465</fpage>
<lpage>467</lpage>
<pub-id pub-id-type="pmid">16048713</pub-id></element-citation></ref><ref id="pctr-0020016-b002"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mills</surname><given-names>E</given-names></name><name><surname>Foster</surname><given-names>BC</given-names></name><name><surname>van Heeswijk</surname><given-names>R</given-names></name><name><surname>Phillips</surname><given-names>E</given-names></name><name><surname>Wilson</surname><given-names>K</given-names></name><etal></etal></person-group>
<year>2005</year>
<article-title>Impact of African herbal medicines on antiretroviral metabolism</article-title>
<source>AIDS</source>
<volume>19</volume>
<fpage>95</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="pmid">15627040</pub-id></element-citation></ref><ref id="pctr-0020016-b003"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harnett</surname><given-names>SM</given-names></name><name><surname>Osthuizen</surname><given-names>V</given-names></name><name><surname>van de Venter</surname><given-names>M</given-names></name></person-group>
<year>2005</year>
<article-title>Anti-HIV activities of organic and aqueous extracts of <named-content content-type="genus-species">Sutherlandia frutescens</named-content> and <named-content content-type="genus-species">Lobostemon trigonus</named-content>
</article-title>
<source>J Ethnopharmacol</source>
<volume>96</volume>
<fpage>113</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="pmid">15588658</pub-id></element-citation></ref><ref id="pctr-0020016-b004"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kundu</surname><given-names>JK</given-names></name><name><surname>Mossanda</surname><given-names>KS</given-names></name><name><surname>Na</surname><given-names>HK</given-names></name><name><surname>Surh</surname><given-names>YJ</given-names></name></person-group>
<year>2005</year>
<article-title>Inhibitory effects of the extracts of <named-content content-type="genus-species">Sutherlandia frutescens</named-content> (L.) R. Br. and <named-content content-type="genus-species">Harpagophytum procumbens</named-content> DC on phorbol ester-induced COX-2 expression in mouse skin: AP-1 and CREB as potential upstream targets</article-title>
<source>Cancer Lett</source>
<volume>218</volume>
<fpage>21</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">15639337</pub-id></element-citation></ref><ref id="pctr-0020016-b005"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chinkwo</surname><given-names>KA</given-names></name></person-group>
<year>2005</year>
<article-title>
<named-content content-type="genus-species">Sutherlandia frutescens</named-content> extracts can induce apoptosis in cultured carcinoma cells</article-title>
<source>J Ethnopharmacol</source>
<volume>98</volume>
<fpage>163</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="pmid">15763378</pub-id></element-citation></ref><ref id="pctr-0020016-b006"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tai</surname><given-names>J</given-names></name><name><surname>Cheung</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>E</given-names></name><name><surname>Hasman</surname><given-names>D</given-names></name></person-group>
<year>2004</year>
<article-title>In vitro culture studies of Sutherlandia frutescens on human tumor cell lines</article-title>
<source>Journal of Ethnopharmacology</source>
<volume>93</volume>
<fpage>9</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="pmid">15182898</pub-id></element-citation></ref><ref id="pctr-0020016-b007"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Katerere</surname><given-names>DR</given-names></name><name><surname>Eloff</surname><given-names>N</given-names></name></person-group>
<year>2005</year>
<article-title>Antibacterial and antioxidant activity of <named-content content-type="genus-species">Sutherlandia frutescens</named-content> (Fabaceae), a reputed anti-HIV/AIDS phytomedicine</article-title>
<source>Phytother Res</source>
<volume>19</volume>
<fpage>779</fpage>
<lpage>781</lpage>
<pub-id pub-id-type="pmid">16220570</pub-id></element-citation></ref><ref id="pctr-0020016-b008"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ojewale</surname><given-names>JA</given-names></name></person-group>
<year>2004</year>
<article-title>Analgesic, anti-inflammatory and hypoglycemic effects of <named-content content-type="genus-species">Sutherlandia frutescens</named-content> R. BR. (variety Incana E. MEY.) [Fabaceae] shoot aqueous extract</article-title>
<source>Methods Find Exp Clin Pharmacol</source>
<volume>26</volume>
<fpage>409</fpage>
<lpage>416</lpage>
<pub-id pub-id-type="pmid">15349136</pub-id></element-citation></ref><ref id="pctr-0020016-b009"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>AC</given-names></name><name><surname>Cromarty</surname><given-names>AD</given-names></name><name><surname>Albrecht</surname><given-names>C</given-names></name><name><surname>Jansen van Rensburg</surname><given-names>CE</given-names></name></person-group>
<year>2004</year>
<article-title>The antioxidant potential of <named-content content-type="genus-species">Sutherlandia frutescens</named-content>
</article-title>
<source>J Ethnopharmacol</source>
<volume>95</volume>
<fpage>1</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">15374599</pub-id></element-citation></ref><ref id="pctr-0020016-b010"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prevoo</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Swart</surname><given-names>P</given-names></name><name><surname>Swart</surname><given-names>AC</given-names></name></person-group>
<year>2004</year>
<article-title>The effect of <named-content content-type="genus-species">Sutherlandia frutescens</named-content> on steroidogenesis: Confirming indigenous wisdom</article-title>
<source>Endocr Res</source>
<volume>30</volume>
<fpage>745</fpage>
<lpage>751</lpage>
<pub-id pub-id-type="pmid">15666820</pub-id></element-citation></ref><ref id="pctr-0020016-b011"><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Seier</surname><given-names>JV</given-names></name><name><surname>Mdhluli</surname><given-names>M</given-names></name><name><surname>Dhansay</surname><given-names>MA</given-names></name><name><surname>Loza</surname><given-names>J</given-names></name><name><surname>Laubscher</surname><given-names>R</given-names></name></person-group>
<year>2002</year>
<source>A toxicity study of <italic>Sutherlandia</italic> leaf powder (<italic><named-content content-type="genus-species">Sutherlandia frutescens</named-content></italic> sub-species <italic>microphylla</italic>) consumption</source>
<publisher-loc>Tygerberg (South Africa)</publisher-loc>
<publisher-name>Medical Research Council</publisher-name>
</element-citation></ref><ref id="pctr-0020016-b012"><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Dalvi</surname><given-names>S</given-names></name></person-group>
<year>2003</year>
<article-title>Sutherlandia for immune support</article-title>
<source>Positive Health</source>
<fpage>23</fpage>
<lpage>25</lpage>
</element-citation></ref><ref id="pctr-0020016-b013"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>RK</given-names></name><name><surname>Pandey</surname><given-names>BL</given-names></name><name><surname>Tripathi</surname><given-names>M</given-names></name><name><surname>Pandey</surname><given-names>VB</given-names></name></person-group>
<year>2001</year>
<article-title>Anti-inflammatory effects of (+)-pinitol</article-title>
<source>Fitoterapia</source>
<volume>72</volume>
<fpage>168</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="pmid">11223227</pub-id></element-citation></ref><ref id="pctr-0020016-b014"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gericke</surname><given-names>N</given-names></name><name><surname>Albrecht</surname><given-names>CF</given-names></name><name><surname>Van Wyk</surname><given-names>B</given-names></name><name><surname>Mayeng</surname><given-names>B</given-names></name><name><surname>Mutwa</surname><given-names>C</given-names></name><etal></etal></person-group>
<year>2001</year>
<article-title>
<named-content content-type="genus-species">Sutherlandia frutescens</named-content>
</article-title>
<source>Aust J Med Herbalism</source>
<volume>13</volume>
<fpage>9</fpage>
<lpage>15</lpage>
</element-citation></ref><ref id="pctr-0020016-b015"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leserman</surname><given-names>J</given-names></name></person-group>
<year>2003</year>
<article-title>HIV disease progression: Depression, stress and possible mechanism</article-title>
<source>Biol Psychiatry</source>
<volume>54</volume>
<fpage>295</fpage>
<lpage>306</lpage>
<pub-id pub-id-type="pmid">12893105</pub-id></element-citation></ref><ref id="pctr-0020016-b016"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosenthal</surname><given-names>GA</given-names></name></person-group>
<year>1997</year>
<article-title>L-Canaline: A potent antimetabolite and anticancer agent from leguminous plants</article-title>
<source>Life Sci</source>
<volume>60</volume>
<fpage>1635</fpage>
<lpage>1641</lpage>
<pub-id pub-id-type="pmid">9129118</pub-id></element-citation></ref><ref id="pctr-0020016-b017"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosenthal</surname><given-names>GA</given-names></name></person-group>
<year>1998</year>
<article-title>A potential chemotherapeutic agent for human pancreatic cancer</article-title>
<source>Pharm Biol</source>
<volume>36</volume>
<fpage>194</fpage>
<lpage>201</lpage>
</element-citation></ref><ref id="pctr-0020016-b018"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Diwinay</surname><given-names>S</given-names></name><name><surname>Chitre</surname><given-names>D</given-names></name><name><surname>Patwardhan</surname><given-names>B</given-names></name></person-group>
<year>2004</year>
<article-title>Immunoprotection by botanical drugs in cancer chemotherapy</article-title>
<source>J. Ethnopharmacol</source>
<volume>90</volume>
<fpage>49</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="pmid">14698508</pub-id></element-citation></ref><ref id="pctr-0020016-b019"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>JY</given-names></name><name><surname>Han</surname><given-names>SK</given-names></name><name><surname>Son</surname><given-names>EH</given-names></name><name><surname>Pyo</surname><given-names>SN</given-names></name><name><surname>Yun</surname><given-names>YS</given-names></name><etal></etal></person-group>
<year>2002</year>
<article-title>Induction of secretory and tumoricidal activities in peritoneal macrophages by ginsan</article-title>
<source>Int Immunopharmacol</source>
<volume>2</volume>
<fpage>857</fpage>
<lpage>865</lpage>
<pub-id pub-id-type="pmid">12188027</pub-id></element-citation></ref><ref id="pctr-0020016-b020"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brown</surname><given-names>DL</given-names></name><name><surname>Naiki</surname><given-names>M</given-names></name><name><surname>Gershwin</surname><given-names>ME</given-names></name></person-group>
<year>2000</year>
<article-title>Does L-canavanine ingestion induce murine SLE? Paradoxical effects on survival of BALB/c mice</article-title>
<source>J Nutr Immunol</source>
<volume>5</volume>
<fpage>17</fpage>
<lpage>27</lpage>
</element-citation></ref><ref id="pctr-0020016-b021"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patwardhana</surname><given-names>B</given-names></name><name><surname>Guatam</surname><given-names>M</given-names></name></person-group>
<year>2005</year>
<article-title>Botanical immunodrugs: Scope and opportunities</article-title>
<source>Drug Discov Today</source>
<volume>10</volume>
<fpage>495</fpage>
<lpage>502</lpage>
<pub-id pub-id-type="pmid">15809195</pub-id></element-citation></ref><ref id="pctr-0020016-b022"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>JP</given-names></name><name><surname>Manheimer</surname><given-names>E</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name></person-group>
<year>2005</year>
<article-title>Herbal medicines for treating HIV infection and AIDS</article-title>
<source>Cochrane Database Syst Rev</source>
<volume>2005</volume>
<comment>CD003937. Available: <ext-link ext-link-type="uri" xlink:href="http://www.cochrane.org/reviews/en/ab003937.html">http://www.cochrane.org/reviews/en/ab003937.html</ext-link>. Accessed 24 March 2007.</comment>
</element-citation></ref><ref id="pctr-0020016-b023"><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mills</surname><given-names>E</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Seely</surname><given-names>D</given-names></name><name><surname>Kanfer</surname><given-names>I</given-names></name></person-group>
<year>2005</year>
<article-title>African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology</article-title>
<source>Nutr J</source>
<volume>4</volume>
<fpage>19</fpage>
<pub-id pub-id-type="pmid">15927053</pub-id></element-citation></ref></ref-list></back></article>